Pipeline — registered trials by phase
Registry of Sustained Immunity to COVID-19 Among ESKD Patients
— · SARS-CoV-2 Infection, Anti-SARS-CoV-2 Infection · Completed · est. 2021-02-12
COVID-19 Progression in End-Stage Kidney Disease
— · SARS-CoV-2 Infection (Asymptomatic), SARS-CoV-2 Infection (Symptomatic) · Completed · est. 2021-04-09
DaVita Assessment of Nutritional Supplement Effects (DANSE)
— · Malnutrition · Completed · est. 2011-01
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where DaVita is lead sponsor; 3 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 10-Q2026-08-04Quarterly report
- 8-K2026-08-04Current report (material event)
- 11-K2026-06-1711-K
- 8-K2026-06-08Current report (material event)
- 10-Q2026-05-05Quarterly report
- 8-K2026-05-05Current report (material event)
- ARS2026-04-22Annual report to holders
- DEFA14A2026-04-22DEFA14A
- DEF 14A2026-04-22Proxy statement
- SCHEDULE 13G/A2026-03-26SCHEDULE 13G/A
- 10-K2026-02-11Annual report
- 8-K2026-02-02Current report (material event)
- 8-K2025-11-25Current report (material event)
- SCHEDULE 13G/A2025-10-30SCHEDULE 13G/A
- 10-Q2025-10-29Quarterly report
- 8-K2025-10-29Current report (material event)
- 8-K2025-08-20Current report (material event)
- 10-Q2025-08-05Quarterly report
- 8-K2025-08-05Current report (material event)
- 8-K2025-07-17Current report (material event)
- 11-K2025-06-1311-K
- 8-K2025-06-09Current report (material event)
- 8-K2025-05-23Current report (material event)
- 8-K2025-05-20Current report (material event)
- 8-K2025-05-20Current report (material event)
- 10-Q2025-05-12Quarterly report
- 8-K2025-05-12Current report (material event)
- SCHEDULE 13G/A2025-04-25SCHEDULE 13G/A
- ARS2025-04-24Annual report to holders
- DEFA14A2025-04-24DEFA14A
- DEF 14A2025-04-24Proxy statement
- 8-K2025-04-14Current report (material event)
- SCHEDULE 13D/A2025-02-13SCHEDULE 13D/A
- 10-K2025-02-13Annual report
- 8-K2025-02-13Current report (material event)
- 10-Q2024-10-29Quarterly report
- 8-K2024-10-29Current report (material event)
- 8-K2024-09-13Current report (material event)
- 8-K2024-09-05Current report (material event)
- 8-K2024-08-14Current report (material event)
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.